GOVX Geovax Labs Inc
GeoVax Labs Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
Company profile
Ticker
GOVX
Exchange
CEO
David A. Dodd
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
IQVIA • PRA Health Sciences • Syneos Health • Incyte • Intrexon • Exelixis • ICON • EXACT Sciences • Sorrento Therapeutics • Tenax Therapeutics ...
Former names
Dauphin Technology Inc
SEC CIK
Corporate docs
IRS number
870455038
GOVX stock data
()
Calendar
13 Aug 19
15 Sep 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 209.94K | 364.23K | 299.3K | 349.34K | |
| Net income | -654.15K | -701.45K | -634.35K | -666.89K | |
| Diluted EPS | -1.01 | -1.43 | -0.01 | 0 | |
| Net profit margin | -312% | -193% | -212% | -191% | |
| Operating income | -653.94K | -701.55K | -634.33K | -667.33K | |
| Net change in cash | 40.43K | -83.72K | -251.54K | 320.27K | |
| Cash on hand | 216.41K | 175.99K | 259.7K | 511.24K |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 963.2K | 1.08M | 828.92K | ||
| Net income | -2.56M | -2.17M | -3.27M | -2.69M | |
| Diluted EPS | -0.02 | -0.03 | -0.08 | -0.08 | |
| Net profit margin | -266% | -202% | -395% | ||
| Operating income | -2.56M | -2.17M | -3.27M | -2.69M | |
| Net change in cash | -53.03K | -141.3K | -606.32K | -41.3K | |
| Cash on hand | 259.7K | 312.73K | 454.03K | 1.06M |
Financial data from Geovax Labs earnings reports
Financial report summary
?Competition
Bristol Myers Squibb • Pfizer • Medimmune • Astrazeneca • Novavax • Protein Sciences • Advaxis • Sanofi • NewLink Genetics • Glaxosmithkline
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Good
|
|
New words:
adjuvant, August, began, called, consortium, defined, dose, effort, Important, lowest, recombinant, Rule, single, smaller, solid, target, trading, tumor, uncertain
Removed:
aim, animal, area, assemble, awarded, capable, derived, elicit, expansion, expertise, financially, half, host, large, patented, pipeline, pursue, recommend, security, variety, VLP
Financial reports
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
13 May 19
10-K/A
2018 FY
Annual report (amended)
12 Apr 19
10-K
2018 FY
Annual report
26 Mar 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
10-Q
2018 Q1
Quarterly report
3 May 18
10-K
2017 FY
Annual report
23 Mar 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
14 Aug 17
Current reports
8-K
GeoVax Reports 2019 Second Quarter Financial Results
14 Aug 19
8-K
GeoVax Issues Shareholder Update Letter
2 Aug 19
8-K
Entry into a Material Definitive Agreement
24 Jul 19
8-K
Entry into a Material Definitive Agreement
17 Jul 19
8-K
Unregistered Sales of Equity Securities
19 Jun 19
8-K
GeoVax Reports 2019 First Quarter Financial Results
14 May 19
8-K
Material Modifications to Rights of Security Holders
30 Apr 19
8-K
Unregistered Sales of Equity Securities
26 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
15 Apr 19
8-K
GeoVax Reports 2018 Year-End Financial Results
27 Mar 19
Registration and prospectus
424B3
Prospectus supplement
8 Nov 18
424B3
Prospectus supplement
7 Aug 18
424B3
Prospectus supplement
3 May 18
424B1
Prospectus with pricing info
3 Apr 18
POS AM
2017 FY
Prospectus update (post-effective amendment)
23 Mar 18
424B3
Prospectus supplement
9 Nov 17
RW
Registration withdrawal request
6 Sep 17
424B3
Prospectus supplement
16 Aug 17
S-1/A
2017 Q1
IPO registration (amended)
13 Jul 17
S-1
2017 Q1
IPO registration
31 May 17
Proxies
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEFA14A
Additional proxy soliciting materials
14 Mar 19
DEF 14A
Definitive proxy
1 Mar 19
PRER14A
Preliminary revised proxy
27 Feb 19
PRE 14A
Preliminary proxy
19 Feb 19
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
27 Apr 18
DEF 14A
Definitive proxy
16 Jun 17
PRE 14A
Preliminary proxy
6 Jun 17
DEF 14A
Definitive proxy
26 Apr 17
Other
EFFECT
Notice of effectiveness
2 Apr 18
EFFECT
Notice of effectiveness
3 Apr 17
EFFECT
Notice of effectiveness
6 Apr 16
CORRESP
Correspondence with SEC
4 Apr 16
CORRESP
Correspondence with SEC
4 Apr 16
UPLOAD
Letter from SEC
31 Mar 16
EFFECT
Notice of effectiveness
30 Mar 16
EFFECT
Notice of effectiveness
30 Mar 16
EFFECT
Notice of effectiveness
30 Dec 15
EFFECT
Notice of effectiveness
10 Sep 15